Executive Summary: Electronic health record and health IT software companies are often valued differently from traditional service businesses because buyers focus less on current earnings alone and more on recurring annual revenue, customer retention, implementation depth, and the difficulty of replacing the platform. Metrics such as annual recurring revenue (ARR), net revenue retention (NRR), deployment […]
Executive Summary: AI-powered diagnostics companies can command valuation premiums because they combine software-like scalability with regulated healthcare economics. For Seattle business owners, the key drivers are FDA clearance status, reimbursement potential, clinical validation strength, recurring licensing revenue, customer concentration, and evidence of durable adoption by hospitals and health systems. In practice, buyers often apply higher […]
Executive Summary: Revenue cycle management (RCM) software valuation centers on how reliably a company converts provider activity into recurring, collectible cash flow. For buyers and investors, the most important indicators are revenue per provider, claim success rates, net revenue retention (NRR), churn, and the degree to which the platform is embedded in a customer’s daily […]
Executive Summary: Valuing a telehealth platform requires more than looking at top-line revenue. Buyers and investors focus on patient visit volume, revenue per visit, payer contract penetration, retention, and how much of the platform’s growth is durable as the market normalizes after the pandemic. The strongest valuations typically come from businesses with recurring revenue characteristics, […]
Executive Summary: Healthtech companies are valued differently than traditional service businesses because their worth depends not only on current earnings, but also on the quality of recurring revenue, patient engagement, clinical evidence, and regulatory readiness. For Seattle business owners in digital health, understanding how ARR, retention, outcomes data, and FDA or other regulatory clearance affect […]
Executive Summary: InsurTech company valuation depends on more than topline growth. Buyers and investors focus on underwriting discipline, revenue durability, policy retention, and the quality of distribution. Loss ratio, combined ratio, premium growth, and retention metrics help determine whether an InsurTech business is creating scalable economics or simply buying growth. Embedded insurance can improve acquisition […]
Executive Summary: Buy-now-pay-later, or BNPL, valuations have shifted from growth-at-all-costs pricing to a sharper focus on unit economics, credit performance, and the durability of merchant economics. For Seattle business owners, investors, and advisers, the most important question is no longer how fast a BNPL platform can expand volume, but whether that volume produces sustainable profit […]
Executive Summary: Neobanks, also called challenger banks or digital banks, are not valued like traditional banks. Investors usually focus less on the book value of capital and more on unit economics, deposit growth, customer acquisition cost, revenue per account, net revenue retention, and the likelihood of reaching sustainable profitability. While traditional banks are often priced […]
Executive summary: Valuing a payment processing company requires more than applying a generic revenue multiple. Buyers and investors focus on total payment volume (TPV), take rate, gross margin, churn, and the durability of the underlying technology. In practice, payment processors with stable TPV growth, disciplined retention, and expanding margins tend to command stronger valuations than […]
Executive Summary: Fintech companies are valued differently than traditional financial services firms because investors pay for scalable technology, recurring revenue, and durable regulatory advantages, not just current earnings. In payments, lending, and neobanking, valuation depends on a mix of revenue multiples, growth quality, unit economics, compliance risk, and customer retention. For Seattle business owners, understanding […]
- 1
- 2